Promising early results from the HERO Trial for MECP2 Duplication Syndrome

Earlier this year, Alvin Luk attended the CRISPR Medicine Conference in Copenhagen to provide an update on the HERO clinical trial for MECP2 Duplication Syndrome. Alvin’s presentation is available for the community to watch on YouTube.

In this video, you’ll learn about Huidagene’s experimental CRISPR-Cas13 therapy, HG204, and see the progress in the first treated child, three months after receiving the investigational drug. Skip to minute 26:00 for video footage of the patient.

These early results are very encouraging and further suggest that restoring MeCP2 protein levels could be a promising strategy to tackle MDS.

A second child has already been treated with HG204, and up to six patients are expected to be enrolled sequentially in this trial in China.

All articles

Published videos

Aleix and his parents talk about his life with MECP2 duplication syndrome

Newsletters

Sign up to the newsletter to stay informed about our work and any scientific developments relating to the syndrome. 

ES Newsletter Form
en_GBEnglish (UK)